<?xml version='1.0' encoding='utf-8'?>
<document id="20145913"><sentence text="Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies." /><sentence text="UDP-glucuronsyltransferases (UGTs) are a family of conjugating enzymes that participate in the metabolism of many drugs" /><sentence text=" The study of potential drug-drug interactions involving UGTs has been largely hindered by the limited availability of selective functional assays for individual UGT enzymes" /><sentence text=" We propose a sensitive and reproducible procedure for the activity measurements of four major human hepatic UGT forms" /><sentence text=" The assays are based on analysis and quantification by high-performance liquid chromatography-tandem mass spectrometry of glucuronides formed from selective probe substrates, namely, beta-estradiol (UGT1A1, 3-glucuronide), 1-naphthol (UGT1A6), propofol (UGT1A9), and naloxone (UGT2B7)"><entity charOffset="123-135" id="DDI-PubMed.20145913.s5.e0" text="glucuronides" /><entity charOffset="184-198" id="DDI-PubMed.20145913.s5.e1" text="beta-estradiol" /><entity charOffset="200-206" id="DDI-PubMed.20145913.s5.e2" text="UGT1A1" /><entity charOffset="208-221" id="DDI-PubMed.20145913.s5.e3" text="3-glucuronide" /><entity charOffset="224-234" id="DDI-PubMed.20145913.s5.e4" text="1-naphthol" /><entity charOffset="236-242" id="DDI-PubMed.20145913.s5.e5" text="UGT1A6" /><entity charOffset="245-253" id="DDI-PubMed.20145913.s5.e6" text="propofol" /><entity charOffset="255-261" id="DDI-PubMed.20145913.s5.e7" text="UGT1A9" /><entity charOffset="268-276" id="DDI-PubMed.20145913.s5.e8" text="naloxone" /><entity charOffset="278-284" id="DDI-PubMed.20145913.s5.e9" text="UGT2B7" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e0" e2="DDI-PubMed.20145913.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e0" e2="DDI-PubMed.20145913.s5.e1" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e0" e2="DDI-PubMed.20145913.s5.e2" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e0" e2="DDI-PubMed.20145913.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e0" e2="DDI-PubMed.20145913.s5.e4" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e0" e2="DDI-PubMed.20145913.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e0" e2="DDI-PubMed.20145913.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e0" e2="DDI-PubMed.20145913.s5.e7" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e0" e2="DDI-PubMed.20145913.s5.e8" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e0" e2="DDI-PubMed.20145913.s5.e9" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e1" e2="DDI-PubMed.20145913.s5.e1" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e1" e2="DDI-PubMed.20145913.s5.e2" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e1" e2="DDI-PubMed.20145913.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e1" e2="DDI-PubMed.20145913.s5.e4" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e1" e2="DDI-PubMed.20145913.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e1" e2="DDI-PubMed.20145913.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e1" e2="DDI-PubMed.20145913.s5.e7" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e1" e2="DDI-PubMed.20145913.s5.e8" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e1" e2="DDI-PubMed.20145913.s5.e9" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e2" e2="DDI-PubMed.20145913.s5.e2" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e2" e2="DDI-PubMed.20145913.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e2" e2="DDI-PubMed.20145913.s5.e4" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e2" e2="DDI-PubMed.20145913.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e2" e2="DDI-PubMed.20145913.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e2" e2="DDI-PubMed.20145913.s5.e7" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e2" e2="DDI-PubMed.20145913.s5.e8" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e2" e2="DDI-PubMed.20145913.s5.e9" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e3" e2="DDI-PubMed.20145913.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e3" e2="DDI-PubMed.20145913.s5.e4" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e3" e2="DDI-PubMed.20145913.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e3" e2="DDI-PubMed.20145913.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e3" e2="DDI-PubMed.20145913.s5.e7" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e3" e2="DDI-PubMed.20145913.s5.e8" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e3" e2="DDI-PubMed.20145913.s5.e9" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e4" e2="DDI-PubMed.20145913.s5.e4" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e4" e2="DDI-PubMed.20145913.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e4" e2="DDI-PubMed.20145913.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e4" e2="DDI-PubMed.20145913.s5.e7" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e4" e2="DDI-PubMed.20145913.s5.e8" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e4" e2="DDI-PubMed.20145913.s5.e9" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e5" e2="DDI-PubMed.20145913.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e5" e2="DDI-PubMed.20145913.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e5" e2="DDI-PubMed.20145913.s5.e7" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e5" e2="DDI-PubMed.20145913.s5.e8" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e5" e2="DDI-PubMed.20145913.s5.e9" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e6" e2="DDI-PubMed.20145913.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e6" e2="DDI-PubMed.20145913.s5.e7" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e6" e2="DDI-PubMed.20145913.s5.e8" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e6" e2="DDI-PubMed.20145913.s5.e9" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e7" e2="DDI-PubMed.20145913.s5.e7" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e7" e2="DDI-PubMed.20145913.s5.e8" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e7" e2="DDI-PubMed.20145913.s5.e9" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e8" e2="DDI-PubMed.20145913.s5.e8" /><pair ddi="false" e1="DDI-PubMed.20145913.s5.e8" e2="DDI-PubMed.20145913.s5.e9" /></sentence><sentence text=" The analytical methods developed in the present study have been validated under good laboratory practice compliance following FDA recommendations" /><sentence text=" The assays can be easily applied to both phenotyping UGT reactions in liver-derived cellular and subcellular systems, and drug-drug interaction in vitro studies" /><sentence text=" Chemical inhibition of UGTs was tested in human liver microsomes at substrate concentrations lower than the corresponding K (M) values" /><sentence text=" Under these conditions, selective inhibition of UGT2B7 by fluconazole and low amitriptyline concentrations were observed, whereas diclofenac and quinidine were shown as non-enzyme-selective inhibitors of UGTs"><entity charOffset="59-70" id="DDI-PubMed.20145913.s9.e0" text="fluconazole" /><entity charOffset="79-92" id="DDI-PubMed.20145913.s9.e1" text="amitriptyline" /><entity charOffset="131-141" id="DDI-PubMed.20145913.s9.e2" text="diclofenac" /><entity charOffset="146-155" id="DDI-PubMed.20145913.s9.e3" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.20145913.s9.e0" e2="DDI-PubMed.20145913.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20145913.s9.e0" e2="DDI-PubMed.20145913.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20145913.s9.e0" e2="DDI-PubMed.20145913.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20145913.s9.e0" e2="DDI-PubMed.20145913.s9.e3" /><pair ddi="false" e1="DDI-PubMed.20145913.s9.e1" e2="DDI-PubMed.20145913.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20145913.s9.e1" e2="DDI-PubMed.20145913.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20145913.s9.e1" e2="DDI-PubMed.20145913.s9.e3" /><pair ddi="false" e1="DDI-PubMed.20145913.s9.e2" e2="DDI-PubMed.20145913.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20145913.s9.e2" e2="DDI-PubMed.20145913.s9.e3" /></sentence><sentence text=" Induction of UGTs was studied in primary human hepatocytes and HepG2 cells cultured in 96-well plates" /><sentence text=" Aryl hydrocarbon receptor ligands (except indirubin in hepatocytes) increased the UGT1A1 activity in both cell models"><entity charOffset="1-17" id="DDI-PubMed.20145913.s11.e0" text="Aryl hydrocarbon" /></sentence><sentence text=" The highest effects were observed in HepG2 cells exposed to indirubin (21-fold over the control) and omeprazole or beta-naphthoflavone (about sixfold)"><entity charOffset="102-112" id="DDI-PubMed.20145913.s12.e0" text="omeprazole" /><entity charOffset="116-135" id="DDI-PubMed.20145913.s12.e1" text="beta-naphthoflavone" /><entity charOffset="143-150" id="DDI-PubMed.20145913.s12.e2" text="sixfold" /><pair ddi="false" e1="DDI-PubMed.20145913.s12.e0" e2="DDI-PubMed.20145913.s12.e0" /><pair ddi="false" e1="DDI-PubMed.20145913.s12.e0" e2="DDI-PubMed.20145913.s12.e1" /><pair ddi="false" e1="DDI-PubMed.20145913.s12.e0" e2="DDI-PubMed.20145913.s12.e2" /><pair ddi="false" e1="DDI-PubMed.20145913.s12.e1" e2="DDI-PubMed.20145913.s12.e1" /><pair ddi="false" e1="DDI-PubMed.20145913.s12.e1" e2="DDI-PubMed.20145913.s12.e2" /></sentence><sentence text=" Although variable effects were observed in other UGT enzymes, the degree of induction was generally lower than that for UGT1A1" /><sentence text="" /></document>